Objective:

To evaluate the efficacy and safety of the VisiPlate glaucoma drainage device in reducing intraocular pressure (IOP) and medication use in patients with open-angle glaucoma.

Key Findings:

• 40% reduction in mean IOP from baseline at 6 months.
• 78% of subjects achieved more than a 20% IOP reduction on the same or fewer medications.
• Medication use decreased from 2.0 to 0.8 medications at 6 months.
• No serious adverse events reported, with most adverse events being self-resolving pain.

Interpretation:

The VisiPlate shunt demonstrates significant potential for reducing IOP and medication burden in glaucoma patients, with a favorable safety profile.

Limitations:

• Small sample size of 15 patients.
• Interim results may not reflect long-term outcomes.

Conclusion:

The VisiPlate shunt shows promise as a new tool in glaucoma treatment, with ongoing efforts for FDA approval.